The healthcare-based subsidiary of Alphabet (GOOGL), Verily, and medical equipment company ResMed (RMD) will join forces to form a JV that will focus on the treatment of sleep apnea and other sleep-related breathing disorders. The partnership aims to create a software that helps in detecting, diagnosing and treating the potentially serious types of sleep disorders.
Verily has entered into several partnerships ever since it became an independent subsidiary of Alphabet in 2015, including pharma giants Johnson & Johnson (JNJ), Sanofi, and Gilead Sciences (GILD). Verily now aims at getting more initiatives into hospitals. Hence, the unit has strengthened its leadership team and has appointed several industry experts to its Board.
The latest JV will combine ResMed’s sleep expertise and Verily’s advanced health data analytics technologies to study the health and financial impacts of undiagnosed and untreated sleep apnea. ResMed has spent years researching sleep apnea, which is a significant health issue in the US. This disorder is said to affect nearly 22 million Americans, most of which remain undiagnosed.
Related: Google’s research firm outstrips pharma rivals in heart disorder prediction
Verily has several promising ongoing projects including controlling the spread of Zika virus, developing glucose-monitoring contact lenses, creating wristbands that helps spot indicators of cancer and heart diseases and many more.
Most Popular
Infographic: Amazon (AMZN) Q4 2024 earnings beat estimates; sales rise 10%
E-commerce giant Amazon.com Inc. (NASDAQ: AMZN) on Thursday reported higher sales and profit for the fourth quarter of 2024. Earnings also beat analysts' estimates. Net sales increased to $187.8 billion
Philip Morris (PM) delivers strong performance in 4Q24 helped by smoke-free strength
Shares of Philip Morris International Inc. (NYSE: PM) jumped 10% on Thursday after the company delivered better-than-expected earnings results for the fourth quarter of 2024 and provided an encouraging outlook
Highlights of Bristol-Myers Squibb’s Q4 2024 earnings report
Biotechnology company Bristol Myers Squibb (NYSE: BMY) reported lower profit for the fourth quarter of 2024, despite an increase in revenue. Net income attributable to shareholders was $72 million or